Medical Communications · EMEA & Asia · Since 2015
Global
evidence.
Local-market
decisions.
Since 2015, we partner with Medical, Brand, and Market Access teams to deliver market-ready scientific communication — evidence generation, launch support, omnichannel content, and HCP engagement.
50+
Pharma clients
10+
Years EMEA
350+
Projects delivered
What brings
you here today?
you here today?
Quick entry — choose your situation
My team works in Medical Affairs
We need payer materials
We're launching a brand
I work in an affiliate team
I need expert consensus
What we do
Our services
For Medical Affairs, Market Access, Brand, and Regional teams across EMEA and Asia.
AI
01
Evidence Dossiers & Clinical Summaries
When local HTA uses a different comparator — we rebuild the argument to fit your market.
Learn more →
02
Advisory Boards & Delphi Consensus
Expert alignment without the 6-month wait. From question design to consensus output.
Learn more →
AI
03
Medical Writing & Publication Planning
Manuscripts, abstracts, posters — from author coordination to journal submission and timeline tracking.
Learn more →
04
Payer Dossiers & HTA Materials
Country-specific value arguments mapped to local HTA decision criteria.
Learn more →
AI
05
RWD & RWE Support
From protocol synopsis to final publication. EDC setup, study design, data collection, analysis, and reporting.
Learn more →
+10
more services
View all 15 →
The core idea of our work
What we
solve
We help pharma teams transform complex evidence into actionable, locally relevant strategies — delivered with speed, precise localization, and seamless alignment across Medical, Marketing, and Market Access.
01
Affiliate localization: got a 200-slide HQ deck, needs a 12-slide country brief by Thursday.
02
Comparator mismatch: local HTA uses a different comparator. The global argument doesn't hold.
03
Congress debrief: ASCO just closed. What changed? What do we update? What do we tell the field?
04
Expert consensus: we need a Delphi advisory — but a classic process takes 6 months.
05
Payer evidence gap: RWE collected in-market but never turned into a usable HTA dossier.
+ more challenges — see the full list →
Real work. Measurable outcomes.
Selected case studies
Ribociclib post-ASCO update: field-ready summary for 12 EMEA markets in 48 hours
✓ MSL teams received updated materials within 48h of congress close
Expert consensus on postmenopausal hormonal therapy: Delphi-based, 65 authors, 5 scientific societies endorsed
✓ Published in high-impact journal, integrated into 2 national guidelines
Patient journey analysis: identifying undiagnosed patients for orphan drug across fragmented diagnostic landscape
✓ Patient-finding algorithm deployed; undiagnosed patients identified
Ready to talk about
your brand?
Tell us what you're working on — we respond within 24 hours.
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Electronic data capture with AI-assisted structuring of unstructured records
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: ribociclib OS data MONALEESA 2023–24
search("ribociclib overall survival", {
years: [2023, 2024],
output: "structured_table"
})
// 847 records → 23 relevant
Processing 847 records...
Evidence Summary
MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...
SolveLetter · Monthly insights
From the field:
evidence & practice
Advisory Boards
What Makes an Advisory Board Truly Insightful? New Trends, Smarter Ideas, and Next-Gen Formats
An advisory board is one of the most intelligent and powerful tools in the pharma arsenal. With the right event architecture, it helps generate valuable insights and build trust within the medical community.
Jun 2025 · SolveLetter #3
Read →
Evidence Strategy
Why Do RWE and RWD Projects Face Challenges, and How Can We Avoid Them?
With evidence generation becoming a key performance indicator for many medical affairs teams, interest in RWE approaches is growing rapidly. Based on experience across a dozen projects, we’ve gathered insights that might be useful.
Apr 2025 · SolveLetter #2
Read →
KOL Engagement
How to Increase Expert (KOL) Engagement in Congresses, Conferences, and Seminars?
Expert engagement at live events is declining. We explore practical solutions and formats that drive real KOL participation and meaningful scientific dialogue.
Feb 2025 · SolveLetter #1
Read →